Doesn't matter at the moment, they're still in the test phase seeing how it interacts with the human body, we're not even up to actual transfusions yet. They have to get over that hurdle before we're talking wide scale use so how much they can produce efficiently isn't the #1 priority right now.

If it causes anaphylactic reactions, doesn't clot or has other negative side effects it's a dead end, go back to the drawing board.